NASDAQ:SPRO Spero Therapeutics Q4 2025 Earnings Report $1.19 -0.04 (-3.25%) Closing price 04:00 PM EasternExtended Trading$1.20 +0.01 (+0.42%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Spero Therapeutics EPS ResultsActual EPS$0.53Consensus EPS -$0.20Beat/MissBeat by +$0.73One Year Ago EPSN/ASpero Therapeutics Revenue ResultsActual Revenue$41.30 millionExpected Revenue$26.00 millionBeat/MissBeat by +$15.30 millionYoY Revenue GrowthN/ASpero Therapeutics Announcement DetailsQuarterQ4 2025Date3/26/2026TimeAfter Market ClosesConference Call DateThursday, March 26, 2026Conference Call Time4:00PM ETUpcoming EarningsSpero Therapeutics' Q3 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Spero Therapeutics Earnings HeadlinesSpero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)September 3, 2026 | globenewswire.comSpero Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment ConferenceSeptember 2, 2026 | globenewswire.comA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.September 28 at 1:00 AM | Porter & Company (Ad)Spero Therapeutics (SPRO) Q2 2026 Earnings Call TranscriptAugust 19, 2026 | finance.yahoo.comSpero Therapeutics, Inc.: Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business UpdateAugust 13, 2026 | finanznachrichten.deSpero outlines cash runway into the second half of 2029 following $105M royalty financingAugust 13, 2026 | seekingalpha.comSee More Spero Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Spero Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Spero Therapeutics and other key companies, straight to your email. Email Address About Spero TherapeuticsSpero Therapeutics (NASDAQ:SPRO) is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The company develops therapies for serious bacterial infections and certain rare diseases, with a focus on addressing conditions for which existing treatment options are limited or inadequate. Spero’s lead program is tebipenem pivoxil hydrobromide, an oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections. The company’s pipeline has also included SPR720, an investigational oral therapy for nontuberculous mycobacterial pulmonary disease, and SPR206, an investigational intravenous antibiotic intended for use against serious hospital infections caused by drug-resistant bacteria. Founded in 2013, Spero has advanced its programs through collaborations and development partnerships, including a former agreement with GlaxoSmithKline. Its research and development activities are primarily focused on the United States, although the potential commercialization of its therapies could involve international markets and partners. Spero’s programs remain subject to clinical, regulatory and commercial development requirements.View Spero Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Brewing Trouble? Starbucks Spills the Beans on 250 Store ClosuresMarketBeat Week in Review – 09/21 - 09/25Analyst Rating Boosts May Signal More Upside for These 3 Stocks3 Stocks Under the Microscope After Large Insider Sales3 Healthcare Stocks Showing Why the Sector Still Has Momentum2 Cybersecurity Stocks Breaking Out as AI Continues to Be a TailwindFertilizer Prices Keep Climbing: 3 Stocks Still Trading at a Discount Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
